RET and non-small cell lung carcinoma: According to the findings of phase 1/2 studies [2,3,4], two selective RET inhibitors, selpercatinib and pralsetinib, received accelerated FDA approval in 2020 for patients with RET fusion-positive non-small cell lung cancer (NSCLC) and thyroid cancer only.